Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
D000328:Adult; D000690:Amyotrophic Lateral Sclerosis / Q000188:drug therapy*; D019992:Databases as Topic; D004311:Double-Blind Method; D004341:Drug Evaluation; D006801:Humans; D016472:Motor Neuron Disease / Q000145:classification / Q000188:drug therapy / Q000453:epidemiology / Q000503:physiopathology; D015337:Multicenter Studies as Topic; D009132:Muscles / Q000503:physiopathology; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D011788:Quality of Life; D016032:Randomized Controlled Trials as Topic; D019782:Riluzole / Q000009:adverse effects / Q000627:therapeutic use*; D012306:Risk; D016019:Survival Analysis; D013997:Time Factors; D016896:Treatment Outcome
D018696:Neuroprotective Agents; D019782:Riluzole